CTLA4 and gastric adenocarcinoma: A randomized phase II (NCT03959293) study with a “stop and go” analysis is evaluating durvalumab with FOLFIRI (folinic acid (leucovorin) + fluorouracil + irinotecan) vs. tremelimumab (a fully human mAb against CTLA-4) and durvalumab with FOLFIRI for advanced gastric adenocarcinoma [40].